AIxCrypto Holdings, Inc. (AIXC): Nasdaq/NYSE listing notice — Qualigen receives Nasdaq delisting notice over delayed 10-K for FY2022

AIxCrypto Holdings, Inc.

Nasdaq notified Qualigen on April 20, 2023 for failing to timely file FY2022 10-K.
Delay attributed to audit complexities from acquiring majority interest in NanoSynex, Ltd.
Company has 60 calendar days (until ~June 19) to submit compliance plan; expects to file 10-K within window.
No immediate effect on listing of common stock (QLGN) on Nasdaq Capital Market.
Failure to regain compliance could lead to delisting from Nasdaq.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 20, 2023, Qualigen Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”), the Company is no longer in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”)

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIxCrypto Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-013314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.